ACCORD

accord

Episode 251: PREMIUM – a new heart failure study and much, much more

In episode 251, PREMIUM Mike and James look at the most recent update of the ACCORD trial and find not a lot. We then look at a relatively new class of medication (neprilysin inhibitor) and actually find something but realise it all needs to be put into context. Read more »

Episode 102: Blood pressure targets: Bullseye or Bulls--t

In episode 102, Mike and James, with laser precision, look at the evidence around blood pressure targets. We cover data in non-diabetics, diabetics, chronic kidney disease and the elderly. At the end they agree that the BP target we used 30 years ago (140/90) is still pretty good. Read more »

Episode 99: Tiotropium, ACCORD and that's it

In episode 99, Mike and James shed light on two useful new trials. We breath air into what to do with patients with asthma who don't respond completely to inhaled corticosteroids and we take a close look with improved visual acuity at the microvascular data from ACCORD. Read more »

Episode 58: Type 2 Diabetes – how sweet it isn’t – Part IV

In episode 58, the fourth in our installment of podcasts on diabetes, we briefly talk about the evidence surrounding intensive glucose lowering (ACCORD, ADVANCE, VADT and UKPDS trials) - podcasts #9 and #38 did this in more detail. Read more »

Episode 29: Creating Confusion or Clarity: Q&A of Listener Mail Part II

In Episode 29, we review questions around informed decision-making, risk-benefits of statins across different populations (women, chronic kidney disease, etc), and comparisons of calculated risks and trial results. We also talk about prescribing of new antimicrobials, differentiating typical from atypical pneumonias and then attempt to clarify a few trials including HOPE. Read more »

Episode 9: News Flash: Aggressive Blood Sugar Control Not All Sweet

In our ninth episode, we interrupt our regularly scheduled podcast to talk about the recently released ACCORD and ADVANCE trials which focus on intensive glucose control (reduction) in diabetes. We discuss the patient-oriented outcomes and harms, ranging from mortality to hypoglycemia, as well as the potential benefits such as preventing microalbuminuria. Read more »

Syndicate content